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Abstract
Background: Long-	term	 sequelae	 of	 acute	 pulmonary	 embolism	 (PE)	 include	 de-
creased	quality	of	life	(QoL).	Evidence	suggests	that	adequacy	of	initial	anticoagulant	
treatment	 in	 the	acute	phase	of	venous	 thrombosis	has	a	key	 impact	on	 late	post-
thrombotic	complications.	We	hypothesize	that	patients	with	acute	PE	treated	with	


















clinical practice setting. We suggest a longitudinal design for investigation of changes 
in	QoL	over	time.
K E Y W O R D S
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1  |  INTRODUC TION
Long-	term	 complications	 in	 patients	 who	 experienced	 acute	
pulmonary	embolism	(PE)	occur	in	about	25%	to	50%	of	patients	
despite	 adequate	 anticoagulant	 treatment.1	 These	 comprise	
symptoms	such	as	dyspnea,	exercise	intolerance,	and	functional	
limitations,	which	persist	 after	 the	 acute	 phase	 and	 are	 called	
post-	PE	 syndrome.2,3	 The	 complaints	 vary	 from	 mild	 symp-
toms	present	during	exercise	only	to	severe	symptoms	at	rest.4 
Diseases	correlated	to	the	post-	PE	syndrome	comprise	chronic	
thromboembolic	 diseases,	 with	 chronic	 thromboembolic	 pul-
monary hypertension as the most feared complication due to 
its poor prognosis.5	The	underlying	pathology	is	thought	to	be	
a	 combination	 of	 inadequate	 thrombus	 resolution,	 persistent	
elevated	 pulmonary	 artery	 pressure,	 and/or	 right	 ventricular	
dysfunction.4,6	In	addition,	anxiety	and	deconditioning	may	also	
contribute	 to	 the	development	of	 the	post-	PE	syndrome.4	The	
proposed	definition	for	diagnosing	post-	PE	syndrome	comprises	
a	 combination	 of	 suggestive	 symptoms,	 objectified	worsening	




life	 (QoL),	 dyspnea,	 and	 exercise	 capacity	 in	 patients	with	 PE	 im-








At	 present,	 therapeutic	 options	 of	 post-	PE	 syndrome	 are	
limited	 to	 treatment	 of	 preexistent	 pulmonary	 and	 cardiac	 co-
morbidities and psychological support.4 In analogy with the 
postthrombotic syndrome in patients with deep vein thrombo-
sis	 (DVT),	quality	of	anticoagulation	may	be	a	risk	factor	for	the	
development	 of	 post-	PE	 syndrome.10	Hence,	 it	 is	 plausible	 that	
adequate	anticoagulant	management	in	the	acute	phase	of	PE	is	
important	 for	 prevention	 of	 post-	PE	 syndrome	 and	 thus	 influ-
ences	QoL.	All	of	the	reported	studies	mentioned	above	included	
only	 patients	 treated	 with	 vitamin	 K	 antagonists	 (VKAs).7,11,12 
In	 the	past	decade,	direct	oral	anticoagulants	 (DOACs)	have	 re-
placed	 VKAs	 as	 the	 drug	 of	 first	 choice	 in	 most	 patients	 with	
acute	venous	 thromboembolism	 (VTE).13	DOACs	are	pharmaco-





that	 is	as	effective	as	warfarin	 for	 treatment	of	acute	VTE,	and	
safer with regards to serious bleeding.14
In	this	study,	we	assessed	whether	patients	with	acute	PE	who	
were	treated	with	edoxaban	had	a	better	QoL	than	those	who	were	
initially treated with warfarin.
2  |  METHODS
2.1  |  Study design and population
The	source	population	for	this	cohort	study	comprised	the	partici-
pants	of	the	Hokusai-	VTE	trial	 (NCT00986154).14	 In	summary,	the	






initial	 therapy	 with	 subcutaneous	 enoxaparin	 for	 at	 least	 5	 days.	




centers based on the number of patients included in the original 









approached for participation in the study by their own study cen-
ter.	 During	 a	 single	 telephone	 visit,	 information	 on	 VTE-	related	
medical history along with comorbidity and comedication was col-
lected.	 After	 the	 telephone	 visit,	 the	 questionnaires	 on	 disease-	
specific	 and	 generic	 health-	related	 QoL	 were	 sent	 to	 patients’	
homes;	patients	were	asked	to	fill	these	out	and	to	return	them	by	
regular	mail	 in	 a	 postage-	paid	 return	 envelope.	 Additionally,	 the	
original	Hokusai-	VTE	trial	database	was	accessed,	and	data	on	pa-
tient	characteristics	during	trial	 inclusion	 (VTE	history,	 thrombus	




local	 review	boards	 in	all	participating	centers.	The	study	was	 regis-
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2.2  |  Study outcomes
2.2.1  |  Outcomes




contains eight dimensions and two summary measures for physical and 





Pulmonary	 Embolism	 Quality	 of	 Life	 (PEmb-	QoL)	 question-









2.3  |  Statistical analysis
Differences in baseline characteristics between both groups were 




treatment	 group	 (edoxaban,	 warfarin)	 was	 assessed	 using	 linear	
regression	analyses,	for	each	dimension	separately.	We	explored	
the	effect	of	potential	 confounders	 in	 two	different	ways.	First,	
potential confounders were assigned by clinical relevance by 




QoL	scores	(outcome).	Characteristics	that	had	a	P value <.25 for 
both univariable associations were considered as a potential con-
founder	 and	were	 included	 in	 a	 second	 full	model.	 For	 both	 full	
models,	we	applied	stepwise	backward	elimination	based	on	 the	
largest P	 value	and	created	a	 final	model	 (that	always	contained	
the	 variable	 “treatment	 allocation”),	 consisting	 of	 variables	with	
a P value <.1.
P values <.05 were considered statistically significant. All anal-
yses	 were	 conducted	 using	 statistical	 software	 SPSS,	 version	 26	
(SPSS	Inc;	Chicago,	IL,	USA).
We performed a sensitivity analysis in the subgroup of patients 
who	were	unaware	of	treatment	allocation	during	the	Hokusai-	VTE	
trial	at	the	moment	of	filling	out	the	QoL	questionnaires.
2.4  |  Data sharing statements
All data relevant to the study are included in the article or uploaded as 
supporting	information.	Data	are	available	upon	reasonable	request.
3  |  RESULTS
Between	 June	 2017	 and	 September	 2020,	 251	 patients	 were	 in-
cluded	in	the	Hokusai	post-	PE	study.	Figure	1	represents	the	flow-
chart	 of	 patient	 inclusions	 in	 this	 study.	 The	 Hokusai-	VTE	 trial	
included	3319	patients	in	439	centers	with	a	PE.14 Of all approached 
F I G U R E  1 Flowchart	of	invited	
participating centers and included 
patients
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83	 centers	 (1547	 Hokusai-	VTE	 trial	 patients),	 58	 centers	 (940	
Hokusai-	VTE	 trial	 patients)	 were	 not	 eligible	 for	 participation	 for	
logistical	 reasons.	 In	 the	 remaining	26	centers,	356	of	 the	original	
607	patients	were	excluded	due	to	death,	 loss	 to	 follow-	up,	or	no	
consent	for	participation,	leaving	251	of	3319	(7.6%)	patients	from	
26	centers	 in	eight	countries	 for	 inclusion.	The	 included	countries	
were	 Australia,	 Belgium,	 Canada,	 France,	 Germany,	 Italy,	 Norway,	
and	the	Netherlands.
3.1  |  Patients and treatment
The	mean	 (standard	 deviation	 [SD])	 time	 from	 randomization	 in	
the	Hokusai-	VTE	 trial	 to	 inclusion	 in	 the	Hokusai	post-	PE	 study	
was	 7	 (1)	 years	 in	 both	 groups.	Of	 the	 251	 patients,	 129	 (51%)	
patients	had	been	allocated	to	edoxaban	during	the	Hokusai-	VTE	
trial,	and	122	(49%)	had	been	allocated	to	warfarin.	Demographic	
and	 clinical	 characteristics	 at	 inclusion	 of	 the	 Hokusai	 post-	PE	
study	were	 comparable	 for	 patients	 treated	with	 edoxaban	 and	





was observed in the proportion of chronic analgesic use between 
patients	treated	with	edoxaban	and	patients	with	PE	treated	with	








Mean	age,	y	(SD) 64	(13.7) 64	(14.7) 65	(13)
Male	sex,	n	(%) 138	(55) 73	(58) 65	(53)
Mean	weight,	kg,	SD 84	(17.6) 84	(16.8) 85	(18.4)
Mean	BMI,	kg/m2	(SD) 28.1	(5.0) 28.0	(4.6) 28.2	(5.5)
Smoking,	n	(%) 28	(11) 14	(11) 14	(11)
≥2	VTE	in	medical	history,	n	(%)b  51	(20) 28	(22) 23	(19)
Comorbidities,	n	(%)
Cardiovascular	diseasec  140	(56) 73	(57) 67	(55)
Malignancy 21	(8) 8	(6) 13	(11)
Musculoskeletal	disease 31	(12) 13	(10) 18	(15)
Neurological	disease 9	(3) 7	(5) 2	(2)
Psychiatric disorder 13	(5) 4	(3) 9	(7)
Concomitant	medication	use,	n	(%)
Any	concomitant	medication	use,	n	(%) 185	(74) 95	(74) 90	(74)
Chronic	analgesic	used  39	(16) 12	(9) 27	(22)
Chronic	anticoagulant	use 88	(35) 45	(35) 43	(36)
DOAC 45(51) 25	(56) 20	(48)
VKA 38	(43) 18	(40) 20	(48)




















TA B L E  1 Demographic	and	clinical	
characteristics	at	inclusion	of	the	Hokusai	
post-	PE	study
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were	 aware	 about	 treatment	 allocation	during	 the	Hokusai-	VTE	
trial	at	 the	 time	of	 filling	out	 the	questionnaires	 for	 the	present	
Hokusai	 post-	PE	 study.	Of	 129	 patients	 allocated	 to	 edoxaban,	
45	(35%)	and	of	the	122	patients	allocated	to	warfarin,	43	(36%),	
were still in use of an anticoagulant drug at the time of filling out 
the	questionnaire.
PE-	related	 aspects	 (ie,	 location	 and	 extent	 of	 PE),	 and	 man-
agement	 of	 PE	 during	 the	 Hokusai-	VTE	 trial	 were	 comparable	 in	
patients	treated	with	edoxaban	and	patients	treated	with	warfarin	
(Table	2).	In	the	edoxaban-	treated	patients,	39	(34%)	had	central	PE,	








TA B L E  2 Characteristics	of	index	PE	at	randomization	of	Hokusai-	VTE	trial
Total (n = 251) Edoxaban (n = 129)a  Warfarin (n = 122)a 
Specific	characteristics	of	PE
Location	of	index	PE,	n	(%)
Central 67	(33) 39	(32) 28	(24)
Segmental 100	(52) 47	(38) 53	(45)
Subsegmental 67	(27) 34	(27) 33	(28)
Bilateral	PE,	n	(%) 167	(67) 86	(68) 81	(69)
Anatomical	extent	of	PE,b 	n	(%)
Extensive 125	(50) 62	(48) 63	(52)
Intermediate 93	(37) 51	(40) 42	(34)
Limited 15	(6) 5	(4) 10	(8)
Not	assessable 18	(7) 11	(9) 7	(6)
Median	NT-	proBNP,	pg/mL	(IQR) 110	(45–	307) 111	(44–	289) 109	(49–	361)
Right	ventricular	dysfunction,c 	n	(%) 27	(11) 13	(10) 14	(11)
Unprovoked	PE,	n	(%) 177	(71) 97	(75) 80	(67)





≥80%	compliance	with	assigned	treatment,	n	(%) 249	(99.6) 128	(100) 121	(99.2)
Mean	percentage	of	time	spent	in	therapeutic	range,d 	SD NA NA 72
Mean	percentage	of	time	spent	in	range	INR	<	2,	SD NA NA 10
Patients	receiving	30	mg	of	edoxaban	at	randomization,e 	n	(%) NA 15	(12) NA
Use	of	concomitant	medication,	n	(%)
Antiplatelet treatment 36	(14) 21	(16) 15	(12)
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which	was	defined	as	an	adherence	rate	of	≥80%.	Concomitant	an-
tiplatelet	 and	 nonsteroidal	 anti-	inflammatory	 drug	 treatment	 was	
used	in	64	(25%)	patients.
Appendix	 S1	 shows	 the	 corresponding	 characteristics	 for	 all	
patients	included	in	the	Hokusai-	VTE	trial	at	the	time	of	random-
ization	 (Appendix	S1,	Table	S1).	 In	our	 study,	 the	overall	 propor-
tion	 of	 patients	with	 an	 unprovoked	PE	 and	 a	 concomitant	DVT	
was	slightly	larger	than	in	the	Hokusai-	VTE	trial.	The	proportion	of	
right ventricular dysfunction and mean percentage of time spent 
in	the	INR	range	<2,	on	the	other	hand,	was	slightly	 lower	 in	our	
study. All other characteristics were similar between the subset 
of patients included in our study and all patients included in the 
Hokusai-	VTE	trial.
3.2  |  Quality of life— SF- 36
Scores	 of	 the	 eight	 dimensions	 and	 the	 two	 summary	 scores	
of	 the	 SF-	36	 for	 patients	 treated	 with	 edoxaban	 and	 patients	









3.3  |  Quality of life— PEMB- QOL







included variables in the adjusted models are presented in detail in 
Appendix	S1	(Table	S3).
A sensitivity analysis in 160 patients who were unaware of their 
allocation	treatment	during	the	Hokusai-	VTE	trial	during	filling	out	
the	QoL	questionnaires	did	not	show	any	large	differences	in	com-
parison	to	 the	analysis	 in	all	251	patients	 (Appendix	S1,	Table	S4).	
In	an	additional	analysis,	we	stratified	patients	still	using	anticoag-
ulants	at	the	time	of	filling	out	the	QoL	questionnaire	and	patients	








F I G U R E  2 Generic	quality	of	life	
in patients with pulmonary embolism 
treated	with	edoxaban	or	warfarin.	Mean	
SF-	36	scores	of	patients	with	a	history	of	
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the	mean	QoL	 difference	 between	 both	 treatment	 arm	 groups.	
Our	adjusted	models	showed	that	sex,	body	mass	index,	and	the	
use of analgesics were prevalent confounders in the association 
between	the	treatment	arm	and	the	different	dimensions	of	QoL.	





We	assessed	 the	outcome	QoL	as	 a	 surrogate	 for	 the	post-	PE	


















contributes to this important topic and may be a foundation for 
further	research	on	the	pathophysiology	of	the	post-	PE	syndrome.	
Studies	 that	 have	 addressed	QoL	 after	 acute	 PE	 have	 been	 con-
ducted	 in	 patients	 on	 VKA	 only	 and	 have	 mostly	 focused	 on	 a	
relatively	 short	 follow-	up	 period	 of	 1	 to	 4	 years	 after	 the	 acute	
PE.7,11,12 We suggest future research to focus on development of 
the	post-	PE	syndrome	over	time	for	different	anticoagulant	treat-
ments.	A	longitudinal	study	with	a	yearly	QoL	assessment	after	the	




















Physical functioning 78.0	(24.1) 74.4	(25.7) 3.6	(−2.6	to	9.8) 1.8	(−4.4	to	8.0) 1.1	(−4.4	to	6.6)
Social	functioning 83.7	(20.4) 81.8	(22.2) 1.9	(−3.4	to	7.2) −0.1	(−5.3	to	5.2) −0.4	(−5.6	to	4.7)
Role physical complaints 78.3	(34.7) 73.3	(40.7) 5.1	(−4.4	to	14.5) 1.5	(−7.8	to	10.8) 0.5	(−8.4	to	9.5)
Role emotional complaints 82.8	(31.9) 81.5	(35.2) 1.3	(−7.1	to	9.6) −1.0	(−9.4	to	7.4) −2.0	(−10.1	to	6.2)
Mental	health 76.6	(18.6) 73.9	(19.2) 2.6	(−2.1	to	7.4) 3.0	(−1.6	to	7.6) 2.9	(−1.6	to	7.4)
Vitality 62.4	(21.2) 59.1	(20.9) 3.3	(−1.9	to	8.6) 1.5	(−3.7	to	6.7) 2.1	(−2.9	to	7.1)
Bodily	pain 72.8	(24.7) 69.0	(28.3) 3.8	(−2.8	to	10.4) 0.6	(−5.7	to	7.0) −0.5	(−6.8	to	5.9)
General	health 65.6	(20.9) 63.4	(20.4) 2.1	(−3.1	to	7.3) 1.4	(−3.8	to	6.7) 1.4	(−3.8	to	6.5)
Summary	mental	score 51.7	(9.1) 50.9	(10.1) 0.8	(−1.6	to	3.2) 0.9	(−1.5	to	3.2) 1.0	(−1.4	to	3.5)
Summary	physical	score 47.1	(9.6) 45.6	(10.4) 1.6	(−0.9	to	4.1) 0.4	(−2.0	to	2.9) 0.0	(−2.3	to	2.3)
PEmb-	QoL,	mean	(SD)
Frequency	of	complaints 85.1	(18.6) 86.8	(19.1) −1.7	(−6.4	to	3) −1.8	(−8.0	to	4.4) −1.1	(−6.6	to	4.4)
ADL	limitations 81.6	(22.6) 81.5	(23.1) 0.1	(−5.6	to	5.8) 0.1	(−5.2	to	5.3) 0.4	(−4.7	to	5.6)
Work-	related	problems 81.7	(34.8) 83.4	(33.1) −1.7	(−10.2	to	6.9) −1.5	(−10.8	to	7.8) −0.5	(−9.5	to	8.4)
Social	interference 92.5	(16.2) 91.7	(18.1) 0.8	(−3.5	to	5.1) 1.0	(−7.4	to	9.4) 2.0	(−6.2	to	10.1)
Intensity of complaints 79.1	(21.7) 80.2	(22.6) −1.2	(−6.7	to	4.3) −3.0	(−7.6	to	1.6) −2.9	(−7.4	to	1.6)
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Additionally,	we	have	 selected	a	 sample	of	 a	 trial	 population,	 po-
tentially	 leading	 to	 limitations	 in	 generalizability.	 The	 high	 adher-




therapy,	 these	 high	 adherence	 rates	may	 explain	why	we	did	 not	
observe a difference between both treatment arm groups.20 
Therefore,	we	need	to	bear	 in	mind	that	our	findings	may	not	re-






according	 to	 the	European	Society	of	Cardiology	classification.	 In	
addition	 hereto,	 recently	 published	 guidelines	 recommend	 indef-
inite	 anticoagulation	 for	most	 of	 the	 patients	 after	 acute	 PE.13,21 
Therefore,	patients	at	highest	risk	for	post-	PE	syndrome	were	un-
derrepresented	 in	Hokusai-	VTE	trial	and	 in	our	subset	of	patients	










dotted purple line is the minimal clinically 
important difference of 10 points as 
described	in	the	Methods	section.	SF-	36,	
36-	Item	Short	Form	Health	Survey
F I G U R E  4 Pulmonary	embolism–	
specific	quality	of	life	in	patients	with	
pulmonary embolism treated with 
edoxaban	or	warfarin.	Results	of	the	
PEmb-	QoL	scores	of	patients	with	a	
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so	that	our	findings	may	not	be	generalizable	to	patients	with	more	
severe	PE.	 In	 line	 herewith,	we	were	 not	 able	 to	 account	 for	 the	
competing	risk	bias	of	mortality	and	had	no	 information	on	treat-
ment allocation in the eligible patients who did not participate in 
this	study.	This	might	have	potentially	led	to	attrition	bias.	However,	
this	seems	unlikely	as	the	demographic	and	clinical	characteristics	
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patients with a history of acute pulmonary 
embolism	treated	with	edoxaban	(n	=	129)	
and	warfarin	(n	=	122).	Scores	are	
presented as mean differences between 
both	groups	with	95%	confidence	
interval.	The	dotted	purple	line	is	the	
minimal clinically important difference 
of 15 points as described in the methods 
section.	PEmb-	QoL,	Pulmonary	Embolism	
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